Although current clinical trials on single-agent programmed cell death protein 1 (PD-1) blockade demonstrated promising results in EOC treatment, the overall response rate is considerably lower than that achieved in melanoma, lung cancer, and renal cell cancer [3]. The gene discussed is PDCD1; the disease is lung cancer.